Published online Jun 14, 2018. doi: 10.3748/wjg.v24.i22.2363
Peer-review started: March 23, 2018
First decision: April 18, 2018
Revised: April 24, 2018
Accepted: April 24, 2018
Article in press: May 26, 2018
Published online: June 14, 2018
Processing time: 80 Days and 5.3 Hours
Core tip: The approach to diagnosis, follow up and management of inflammatory bowel disease (IBD) has undergone a major transformation in the past decade. Many different international quality indicators that span structure, process and outcome measures have been developed. These serve as major targets in optimizing quality of care (QoC). New developments have been designed to improve QoC including utilizing telemedicine, home biomarker testing and providing rapid access care to patients. Treating to target with proactive disease management guided by clinical history utilizing adjunctive biomarkers at the onset of IBD has been shown to improve objective outcomes. This will likely serve as the new favored treatment approach in many IBD centers across the globe.
